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Total cholesterol/HDL cholesterol ratio
Objective: The plasma leptin/adiponectin (L/A) ratio has been proposed as a preferential marker of
atherosclerosis susceptibility compared to leptin and adiponectin alone. We determined the extent to
which the L/A ratio predicts incident cardiovascular disease (CVD) taking account of clinical risk factors,
microalbuminuria, the total cholesterol/HDL cholesterol (TC/HDL-C ratio), triglycerides, high sensitive
C-reactive protein (hs-CRP) and insulin sensitivity (homeostasis model assessment (HOMAir)).
Methods: A community-based prospective nested case–control study was carried out in 103 non-diabetic
men who developed a ﬁrst cardiovascular event (cases) and 106 male control subjects (no clinically manifest
CVD and no lipid lowering drug use at baseline; median follow-up of 3.0 and 10.5 years, respectively). Plasma
leptin, adiponectin, the leptin/adipnectin (L/A) ratio, as well as hs-CRP, HOMAir and the TC/HDL-C ratio were
determined at baseline.
Results: Plasma leptin levels and the L/A ratio were higher in cases vs. controls (p=0.002 for both), but the
difference in adiponectin was not signiﬁcant (p=0.10). Age-adjusted incident CVD was associated with
plasma leptin, adiponectin and the L/A ratio (p=0.045 to p=0.001). The relationships of incident CVD
with plasma leptin (p=0.19) and adiponectin (p=0.073) lost statistical signiﬁcance after additional
adjustment for smoking, waist circumference, hypertension, microalbuminuria, the TC/HDL-C ratio, hs-CRP
and HOMAir. In this fully adjusted analysis, the L/A ratio remained predictive of incident CVD (hazard
ratio: 1.40 (95% CI 1.05–1.87), p=0.024).
Conclusion: This study suggests that the L/A ratio may be a preferential marker of a ﬁrst cardiovascular event
in men compared to plasma leptin and adiponectin levels alone.© 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. Introduction
Leptin and adiponectin are secreted by adipose tissue, and represent
the most abundant adipokines in human plasma [1–5]. Despite
intensive study, the relevance of leptin and adiponectin in cardiovascu-
lar disease (CVD) prediction is still unsettled. Although high plasma
leptin levels predict incident CVD, this relationship is to a considerable
extent attenuated by obesity [6]. A meta-analysis revealed that higher
plasma adiponectin levels confer only a modest cardioprotective effect
[7]. Intriguingly, pro-atherogenic effects of leptin and anti-atherogenic
effects of adiponectin could paradoxically disappear in people who are
already suffering from advanced atherosclerosis [8,9].ogy, University Medical Center
erlands. Tel.: +31 503613731;
laart).
ation of Internal Medicine. PublisheBased on intima–media thickness and other surrogate outcome
measures it has been proposed that the L/A ratio may be preferable
over separate leptin and adiponectin measurements in CVD risk
assessment [10–13], but the advantage of the L/A ratio in predicting
subclinical atherosclerosis is uncertain [14,15]. Information concerning
the relevance of the L/A ratio in clinical cardiovascular outcome predic-
tion is limited. In theMonica/KORAAugsburg studies, incident CVDwas
related to plasma levels of leptin, adiponectin, as well as to the L/A ratio
in age-, sex- and survey-adjusted analyses [16]. Of note, none of these
adipokinemeasures predicted incident CVD after additional controlling
for clinical and non-clinical risk factors [16].
It is well appreciated that plasma levels of high-sensitive C-reactive
protein (hs-CRP), as a marker of chronic subclinical inﬂammation, are
correlated positively to plasma leptin and inversely to adiponectin
[17–19]. Of further importance, various measures of insulin sensitivity
are strongly dependent on the L/A ratio, emphasizing the role of
adipocyte dysfunction in the pathogenesis of insulin resistance [20]. It
is, therefore, relevant to take account of chronic subclinical inﬂammationd by Elsevier B.V. All rights reserved.
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lar outcome with the L/A ratio.
In the present study, we determined the extent to which inci-
dent CVD is associated with the L/A ratio. To this end a prospective
nested case–control study was carried out among participants of
the community-based Prevention of Renal and Vascular End-stage
Disease (PREVEND) cohort. The setup of this study enabled us to
take account of conventional clinical and non-clinical risk factors,
microalbuminuria, hs-CRP and insulin sensitivity.
2. Subjects and methods
2.1. Study population and design
The local medical ethics committee approved the study, and all
participants gave written informed consent. The present prospective
nested case–control study was carried out among participants of the
PREVEND cohort. Details of the PREVEND study have been published
elsewhere (www.PREVEND.org, [21]). The PREVEND study comprises
a prospective study in a predominantly Caucasian population that
was started in 1997. To this end all inhabitants of the city of
Groningen, the Netherlands, aged 28 to 75 years were sent a ques-
tionnaire and a vial to collect a ﬁrst-morning-void urine sample
(prescreening). Of these subjects, 40,856 responded (47.8%) and
returned a vial to a central laboratory for urinary albumin and creat-
inine assessment. After exclusion of patients with insulin-treated
diabetes mellitus and pregnant women, all subjects with a urinary
albumin concentration of ≥10 mg/L (n=7768) were invited of
which 6000 participated. Furthermore, 3394 randomly selected sub-
jects with a urinary albumin concentration of b10 mg/L were invited
of which 2592 participated. These 8592 subjects participated in the
baseline screening and constitute the actual PREVEND cohort.
Men without a history of myocardial infarction, major ischemia,
percutaneous transluminal coronary angioplasty or coronary artery
bypass graft at baseline were eligible for the present nested case–con-
trol study, as described [21]. Diabetes mellitus, use of lipid lowering
drugs and urinary albumin excretion >300 mg/24 h at baseline
were additional exclusion criteria. Initial selection of cases was men
who experienced an event during follow-up as deﬁned below. The
original time frame of observation included the period from enrol-
ment (1997) until 31 December 2003 or 31 December 2002 until
which date information regarding speciﬁc causes of death follow up
information was available [23]. For the present study an extended
follow-up, censored at 31 December 2008 was used. Control subjects
were randomly selected from the baseline sample applying similar
exclusion criteria as for the cases [21]. The current report includes
103 cases and 106 controls in whom in addition to serum lipids, apo-
lipoproteins (apos), insulin and hs-CRP, plasma adiponectin, leptin
measurements were available.
Since the matching variable may not be the confounding factor,
but may make part of a causal pathway linking exposure to outcome,
cases were not individually matched with control subjects with
respect to age and other clinical variables, thereby following the
methodological approach as proposed by O.S. Miettinen [22]. As a
consequence, we controlled for confounding and effect modiﬁcation
using multivariable analyses.
The combined end-point was incident cardiovascular disease (CVD),
deﬁned as death from CVD, hospitalization for myocardial infarction,
percutaneous transluminal coronary angioplasty or coronary artery by-
pass grafting [21]. Veriﬁcation of the vital status, causes of death and of
cardiovascular end-point was performed as described [21]. Body mass
index (BMI) was calculated as the ratio between weight and height
squared (in kg/m2).Waist circumferencewasmeasured on bare skin be-
tween the 10th rib and the iliac crest. Hypertension was deﬁned as sys-
tolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm
Hg or the use of antihypertensive drugs. Insulin resistancewas estimatedusing homeostasismodel assessment (HOMAir), andwas calculatedwith
the equation: fasting plasma insulin (mU/L)×glucose (mmol/L)/22.5.
Microalbuminuria was deﬁned as urinary albumin excretion between
30 and 300 mg/24 h based on two 24 h urine collections.
2.2. Laboratory analyses
Serum and ethylenediaminetetraacetic acid-anticoagulated plasma
samples were stored at−80°C until analysis. Plasma glucose was mea-
sured shortly after blood collection. Total cholesterol (TC), high density li-
poprotein cholesterol (HDL-C), triglycerides and glucose were measured
as described [21,23]. Non-HDL cholesterol (non-HDL-C) was calculated
as the difference between plasma total cholesterol and HDL-C. Apolipo-
protein (apo) B and apoA-I were determined by nephelometry using
commercially available reagents [23]. Plasma leptin was analyzed using
Luminex xMAP technology (Linco Research Inc. St. Charles, MO, USA,
Lincoplex panel B (HADK-2-61K-B). Validation experiments have
shown that leptin levels measured with this technology are strongly cor-
related with assay results obtained by enzyme-linked immunosorbent
assay (ELISA) obtained from Linco Inc. ([24]; data provided by themanu-
facturer). Total adiponectin was measured by enzyme-linked immuno-
sorbent assay (Linco Research Inc., St. Charles, MO, USA, cat no
EZHADP-61k). The within-assay coefﬁcients of variation for leptin and
adiponectin were 8.9% and 6.4%, respectively. Insulin was measured by
microparticle enzyme immunoassay (AxSYM Insulin assay; Abott Labora-
tories, Abbott Park IL, USA). hs-CRPwasmeasured by nephelometry with
a threshold of 0.18 mg/L [23].
2.3. Statistical analyses
SPSS 18 was used for data analysis. Two-sided p-values≤0.05
were considered signiﬁcant.
Data are expressed as mean±SD or in median (interquartile
range). Differences in variables between cases and controls were
compared with unpaired Student's t-tests. Between group differences
in dichotomous variables were compared by χ2-analysis. Because of
skewed distribution, logarithmically transformed values of leptin,
adiponectin, the L/A ratio, triglycerides, hs-CRP, insulin and HOMAir
were used in the analysis. Between group differences in leptin,
adiponectin and the L/A ratio were also determined after controlling
for age. Univariate relationships were assessed by Pearson's correla-
tion coefﬁcients.
Associations between incident CVD and plasma levels of leptin,
adiponectin and the L/A ratio were determined using age-adjusted
Cox proportional hazards analyses. The date of a ﬁrst event was
used to calculate duration of follow-up. The proportional hazards
assumption was not violated in any of the models. Hazard ratios
(HRs) are reported per SD change with 95% conﬁdence interval
(95% CI). HRs of adipokines and the L/A ratio were also determined
after further adjustment for clinical variables, the TC/HDL-C ratio,
triglycerides and microalbuminuria, as well as after additional
adjustment for HOMAir and hs-CRP. We used Cox proportional hazard
analyses, because some controls were lost to follow-up before census
date.
The whole PREVEND cohort consists of a random sample of subjects
with urinary albumin concentration b10 mg/L and all subjects with uri-
nary albumin concentration ≥10 mg/L [25]. Since enrichment for
subjects with higher degrees of albuminuria could induce bias due
to oversampling of subjects with urinary albumin concentration
≥10 mg/L, we also estimated risk in a sensitivity analysis. This sensitiv-
ity analysis was done among those subjects included in the present
nested case–control studywhomade part of the so-called “randomsam-
ple” of the PREVEND cohort, i.e. all subjects with urinary albumin con-
centration b10 mg/L and a subset of subjects with urinary albumin
concentration ≥10 mg/L, exactly as described previously [25].
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Median follow-up was 3.0 (10th to 90th percentile, 0.9–5.8) years in
cases and 10.5 (10th to 90th percentile, 9.1–11.1) years in control sub-
jects. Cases were older, more obese, smoked more frequently, had a
higher prevalence of hypertension and microalbuminuria, had higher
hs-CRP levels and were more insulin resistant compared to control
subjects (Table 1). Plasma TC, non-HDL-C, the TC/HDL-C ratio and triglyc-
erides were higher, whereas HDL-C was lower in cases. Likewise, apoB
and the apoB/apoA-I ratio was increased, whereas apoA-I was decreased
in cases. Plasma leptin levels and the L/A ratio were elevated in cases,
although the difference in adiponectin was not signiﬁcant (Table 1). In
age-adjusted analyses, plasma adiponectin (p=0.013) and the L/A ratio
(p=0.006) were different in cases compared to controls, but the
difference in plasma leptin did not reach signiﬁcance (p=0.065).
In all subjects combined, leptin and the L/A ratio were correlated
positively with waist, HOMAir, hs-CRP, albuminuria, the TC/HDL-C
ratio, the apoB/apoA-I ratio and triglycerides (Table 2). Adiponectin
was correlated inversely with waist, HOMAir, the TC/HDL-C ratio,
the apoB/apoA-I ratio and triglycerides. Comparable relationships of
the leptin, adiponectin and the L/A ratio with these variables were ob-
served in cases and control subjects separately (Table 2). The L/A ratio
was neither signiﬁcantly correlated with age in all subjects combined
(r=0.108, p=0.121), nor in cases (r=-0.082, p=0.423) and in con-
trol subjects (r=0.092, p=0.346) separately.
As shown in Table 2 (models 1), age-adjusted incident CVD was as-
sociated positively with leptin and inversely with adiponectin. Incident
CVD was also positively predicted by the L/A ratio with the point esti-
mate of the hazard ratio for CVD being slightly higher than that of plas-
ma leptin alone. After additional adjustment for smoking, waist
circumference, hypertension, microalbuminuria, the total cholesterol/
HDL cholesterol ratio and triglycerides (models 2), the relationships of
incident CVDwith leptin, adiponectin and the L/A ratio remained signif-
icant (models 2). The relationships of incident CVD with leptin and
adiponectin were, however, no longer statistically signiﬁcant after
further controlling for hs-CRP and HOMAir (models 3). Of note, the L/A
ratio remained predictive of incident CVD in this fully adjusted model.
Alternatively, in fully adjusted analyses with the apoB/apoA-I ratioTable 1
Clinical characteristics, microalbuminuria, plasma glucose, high sensitive C-reactive
protein (hs-CRP), insulin sensitivity (homeostasis model assessment (HOMAir)), lipids
and apolipoproteins (apos), leptin, adiponectin and the leptin/adiponectin (L/A) ratio






Age (years) 58±10 47±12 b0.001
BMI (kg/m2) 27.0±3.5 25.8±3.2 0.009
Waist circumference (cm) 97±10 92±9 b0.001
Hypertension (n, %) 58 (56%) 31 (29%) b0.001
Smoking (n, %) 57 (55%) 38 (36%) 0.005
Microalbuminuria (n, %) 31 (30%) 14 (13%) 0.007
hs-CRP (mg/L) 2.09 (1.10–3.54) 0.97 (0.46–2.71) b0.001
Glucose (mmol/L) 4.9±0.7 4.8±0.6 0.29
Insulin (mU/L) 9.7 (6.6–13.8) 7.3 (5.4–10.3) 0.028
HOMAir (mU×mmol/
(L2×22.5))
2.0 (1.5–3.0) 1.6 (1.1–2.3) 0.002
Total cholesterol (mmol/L) 6.18±1.16 5.58±1.03 b0.001
HDL cholesterol (mmol/L) 1.06±0.35 1.21±0.32 0.002
TC/HDL-C ratio 6.41±2.22 4.96±1.60 b0.001
Triglycerides (mmol/L) 1.60 (1.07–2.38) 1.17 (0.84–1.55) b0.001
Apo B (g/L) 1.23±0.38 1.06±0.25 b0.001
Apo A-I (g/L) 1.24±0.27 1.33±0.0.22 0.005
ApoB/ApoA-I ratio 1.04±0.36 0.82±0.23 b0.001
Leptin (μg/L) 3.92 (2.34–7.54) 2.89 (2.01–5.00) 0.002
Adiponectin (mg/L) 15.56 (9.52–30.09) 19.97 (11.54–30.51) 0.10
L/A ratio (μg/mg) 0.26 (0.12–0.56) 0.16 (0.08–0.32) 0.002
Data in mean±SD or in median (interquartile range). BMI, body mass index; HDL, high
density lipoproteins; and TC/HDL-C ratio, total cholesterol/HDL cholesterol ratio.instead of the TC/HDL-C ratio (cf. models 3) the relationships of incident
CVD with plasma leptin (HR 1.21 (95% CI, 0.91–1.61), p=0.19) and
adiponectin (HR 0.82 (95% CI, 0.60–1.02), p=0.073)) were again not
signiﬁcant, whereas the L/A ratio still predicted CVD (HR 1.38 (95% CI,
1.03–1.85), p=0.03) (Table 3).
A sensitivity analysis was carried out among subjects making part of
the so-called random sample of the PREVEND cohort. This analysis
again revealed that CVD risk was associated with the L/A ratio (model
1: HR 1.35 (95% CI 1.08–1.70), p=0.009; model 2: HR 1.49 (95% CI
1.11–2.01), p=0.009;model 3: HR 1.37 (95% CI 0.98–1.90), p=0.062).
4. Discussion
This prospective nested case–control study demonstrates that in
age-adjusted analyses incident CVD is positively related to plasma
leptin and the L/A ratio, and inversely to plasma adiponectin. Thus,
in this study among men without clinically manifest atherosclerosis
at baseline there was no evidence for a putative reverse epidemiology
phenomenon, which has been implicated in paradoxically opposite
relationships of these adipokines with CVD in elderly people and in
subjects with advanced manifestations of atherosclerotic disease
[8,9,26]. Moreover, after additional adjustment for clinical risk factors,
as well as for plasma lipids and microalbuminuria, the association of
incident CVD with all these adipokine measures remained statistically
signiﬁcant. Of note, in fully adjusted models in which we also
accounted for chronic subclinical inﬂammation and insulin sensitivi-
ty, only the relationship of incident CVD with the L/A ratio remained
statistically signiﬁcant. The current study, therefore, suggests that the
L/A ratio may be a preferential marker of adipokine-associated ﬁrst
cardiovascular events in predominantly middle-aged men compared
to plasma leptin and adiponectin levels alone.
It is likely that leptin and adiponectin contribute to the pathogen-
esis of (obesity-related) atherosclerosis via several interrelated meta-
bolic pathways, including effects on inﬂammatory processes and
modulation of insulin sensitivity [1–5]. In addition, adiponectin may
directly affect the synthesis of apoA-I, the major HDL apolipoprotein,
as well the metabolism of triglyceride-rich lipoproteins [27,28]. As
expected, the L/A ratio was strongly correlated with the waist circum-
ference, hs-CRP, HOMAir, the TC/HDL-C ratio and triglycerides
[17–20]. We also observed a correlation with higher urinary albumin
excretion, which is considered a cardiovascular risk marker as well
[29,30]. These robust relationships underscore the necessity to take
account of all these factors when evaluating the extent to which lep-
tin, adiponectin and the L/A ratio may predict incident CVD. Indeed,
we found no statistically independent effects of plasma leptin and
adiponectin levels alone on incident CVD in fully adjusted analyses.
The currently documented independent contribution of the L/A
ratio to ﬁrst cardiovascular events even in fully adjusted analysis
needs to be compared with the results of the prospective Monica/
KORA Augsburg studies that comprised middle aged men and
women who were initially free of clinically manifest coronary heart
disease. In that report, no independent effect of the L/A ratio on inci-
dent CHD could be demonstrated [16]. Although the precise reasons
for the apparent discrepancy remain to be clariﬁed, there are several
methodological differences. The Monica/KORA Augsburg report had a
case–cohort design and included higher numbers of men and women,
whereas recruitment of subjects was carried out at multiple surveys.
In the PREVEND project, in contrast, subject recruitment was carried
out within a limited time frame. Furthermore, the current study had
a nested case–control design, making that the number of participants
in our study was smaller. In addition, we adjusted for hypertension
and the presence of microalbuminuria. The Monica/KORA Augsburg
report took account of physical activity and alcohol consumption.
On the other hand, both studies used essentially similar clinical car-
diovascular end-points, and accounted for lipoprotein-related risk
primarily by using the TC/HDL-C ratio, which has emerged as a
Table 2
Pearson's correlation coefﬁcients of leptin, adiponectin and the leptin/adiponectin (L/A) ratio with waist circumference, insulin sensitivity (homeostasis model assessment (HOMAir), high







Leptin Adiponectin L/A ratio Leptin Adiponectin L/A ratio Leptin Adiponectin L/A ratio
Waist 0.597‡ −0.285‡ 0.586‡ 0.587‡ −0.364‡ 0.617‡ 0.597‡ −0.155 0.586‡
HOMAir 0.627‡ −0.211† 0.564‡ 0.597‡ −0.158 0.490‡ 0.622‡ −0.233⁎ 0.594‡
hs-CRP 0.273‡ −0.113 0.258‡ 0.186 −0.134 0.207⁎ 0.254† −0.034 0.209⁎
UAE 0.192† −0.082 0.183† 0.167 −0.073 0.156 0.110 −0.022 0.095
TC/HDL-C ratio 0.273‡ −0.247‡ 0.337‡ 0.152 −0.266† 0.269† 0.306‡ −0.157 0.316‡
Triglycerides 0.286‡ −0.263‡ 0.355‡ 0.217⁎ −0.227⁎ 0.287† 0.262† −0.262† 0.342‡
ApoB/ApoA-I ratio 0.237‡ −0.243‡ 0.309‡ 0.077 −0.265† 0.220⁎ 0.326‡ −0.142 0.323‡
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lipoprotein measures [23,31]. In view of the relationship of the L/A
ratio with plasma triglycerides, we controlled for triglycerides as well.
Of additional relevance, the apoB/apoA-I ratio provides an at least
equally strong lipoprotein risk factor compared to the TC/HDL-C ratio
[23,32,33]. Therefore, analyses with this apolipoprotein ratio instead
of the TC/HDL-C ratio were also carried out. In the current study, the
L/A ratio was an independent CVD risk predictor in apoB/apoA-I
ratio-adjusted analysis as well.
Several other methodological aspects of our study require
consideration. We included men only in the expectation that too few
events would occur in women to allow for meaningful sex-speciﬁc
analysis, as is required in view of the marked sexual dimorphism of
leptin and adiponectin in post-pubertal subjects [24]. Furthermore,
case deﬁnition was conﬁned to cardiac outcomes in order to reduce
heterogeneity among cardiovascular end-points [21]. Thus, our results
do not necessarily hold true for women or for other cardiovascular risk
domains. Furthermore, it should be appreciated that the PREVEND
cohort is enriched with microalbuminuric subjects [25]. A sensitivity
analysis among the subset of subjects derived from the so-called ran-
dom sample of the PREVEND cohort, i.e. that part of the cohort that is
randomly selected from the Groningen city population [25], revealed
essentially similar point estimates of the L/A ratio-associated hazard in
age-adjusted as well as in fully adjusted analyses compared to the haz-
ard ratios obtained in the whole current study group. Important bias
attributable to preferential participation of microalbuminuric subjects
is, therefore, unlikely. Finally, it should be noted thatwe assayed plasma
total adiponectin, although several isoforms with different biological
activity are present in the circulation [2].
In conclusion, the present prospective nested case–control study
suggests that the L/A ratio may be a preferential marker of
adipokine-associated ﬁrst cardiovascular events in predominantly mid-
dle aged men compared to plasma leptin and adiponectin levels alone.Table 3
Hazard ratios (HRs with 95% conﬁdence intervals, CI) of leptin, adiponectin and the leptin/
analysis. HRs are given per 1 SD increase.
Model 1 Model 2
HR (95% CI) p-value HR (95%
Leptin 1.25 (1.01–1.55) 0.045 1.32 (1.0
Adiponectin 0.74 (0.62–0.89) 0.001 0.80 (0.6
L/A ratio 1.40 (1.14–1.71) 0.001 1.50 (1.1
Leptin, adiponectin and the L/A ratio values are logarithmically transformed.
Models 1: adjusted for age.
Models 2: adjusted for age, smoking, waist circumference, hypertension, microalbuminuria
Models 3: adjusted for age, smoking, waist circumference, hypertension, microalbuminuria,
tein and insulin sensitivity (homeostasis model assessment).Learning points
• The plasma leptin/adiponectin (L/A) ratio has been proposed as a
preferential marker of adipokine-related atherosclerosis susceptibility.
• This community-based prospective nested-case control study among
predominantly middle-aged men who were initially free of clinically
manifest cardiovascular disease demonstrates that the L/A ratio
remains predictive of ﬁrst cardiovascular events after controlling of
clinical and non-clinical riskmarkers, including chronic subclinical in-
ﬂammation and insulin sensitivity.
• With plasma leptin and adiponectin levels alone no such independent
relationships with incident cardiovascular disease were observed.
• This study suggests that the L/A ratio may be a preferential marker
of adipokine-associated ﬁrst cardiovascular events in men.
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